Previous 10 | Next 10 |
University of Nottingham scientists have developed a new quantum therapeutic approach to treating cancer that could treat one of the most aggressive types of brain cancer, glioblastoma. The researchers created a new spray treatment capable of treating glioblastoma through quantum signaling, mak...
A multi-institutional team of researchers has developed a novel type of cellular immunotherapy that has proven its therapeutic effectiveness in mouse models. Comprised of a researcher from the German Cancer Research Center and a University Medical Center Mannheim physician, the team used ...
Researchers from Boston Children’s Hospital say they have created a prototype surgical tool that can allow surgeons to remove pediatric brain tumors safely and in a less invasive manner. The surgical robot uses hollow, nitinol robot arms to give surgeons the ability to switch tools...
CNS Pharmaceuticals is conducting a global clinical trial to evaluate its flagship drug candidate for treating glioblastoma, a deadly brain cancer CNS has enrolled 200 of its planned 243 patients for its clinical trial roster, and anticipates filling out the remainder of patients by year’...
Nottingham University researchers have devised a novel means of treating brain cancer that could signal a “ quantum leap” in brain-tumor treatments moving forward. A multidisciplinary research team created a new way of targeting and eliminating cancer cells in typically hard-...
CNS Pharmaceuticals (NASDAQ: CNSP) , a clinical-stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, glioblastoma (“GBM”) and neuro-oncology, recently presented updated safety results from its potentially pivotal clinical stud...
Brigham and Women’s Hospital scientists have developed a microdevice to help researchers test the effectiveness of glioma treatments. Gliomas are a type of brain tumor that arise from glial cells in the spinal cord and brain before infiltrating surrounding brain cells. Because the ...
University of California Los Angeles (UCLA) scientists have published research findings that could provide deeper insight into why some types of brain tumors respond to immunotherapy while others don’t. While many types of brain tumors typically respond to immunotherapy, an aggressive ty...
CNS Pharmaceuticals recently announced updated results from its pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin The novel anthracycline demonstrated its capability to be an innovative potential treatment option for GBM 151 patients have been enrolled in the ...
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced enrollment of 200 of the expected 243 patients in the company’s ongoing potential...
News, Short Squeeze, Breakout and More Instantly...
CNS Pharmaceuticals Inc. Company Name:
CNSP Stock Symbol:
NYSE Market:
CNS Pharmaceuticals Inc. Website:
New research suggests that cancer may have been plaguing individuals even thousands of years ago. Researchers at the University of Cambridge’s Duckworth Laboratory Collection studied skulls obtained from Ancient Egypt, observing lesions which they believe may have been left by malignant t...
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in tomorrow’s Virtual Investor Closing Bell Series. According to the announcemen...
Live video webcast with Chief Executive Officer, John Climaco, on Wednesday, June 17 th at 4:00 PM ET HOUSTON, TX / ACCESSWIRE / July 16, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatm...